Achillion Pharmaceuticals, Inc (ACHN) reported positive interim results from a phase II study (n=12) on its hepatitis C virus (HCV) candidate, ACH-3102. The company’s shares jumped 9.6% following the news. The mid-stage study is evaluating a ribavirin-free regimen of ACH-3102 in combination with Gilead’s (GILD) Sovaldi (sofosbuvir) for the treatment of patients suffering from treatment-naïve genotype 1 chronic HCV infection for eight weeks. Results from … Continue reading Biotech Stocks Highlight for the Week: Achillion Pharmaceuticals Soars Due to Positive Test Results